Investment
Features
FeesSafety
Academy
More
Pluang+

Wolters Kluwer repurchases 107,852 shares for €6.9M as part of €500M 2026 buyback plan

Company Fundamentals
26 Mar 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Wolters Kluwer repurchased 107,852 of its own shares between March 19 and March 25, 2026, spending €6.9 million at an average price of €64.35 per share. This is part of a larger share buyback program announced in February 2026, aiming to repurchase up to €500 million worth of shares during the year. So far, the company has bought back 1,772,050 shares totaling €130.1 million. The repurchased shares are held as treasury shares and will be used for capital reduction through share cancellation. A third party has been engaged to execute €60 million of buybacks from February 27 to May 4, 2026, within legal limits.

More News

Global automotive microcontrollers market to reach $34.31B by 2035, driven by ADAS, electrification, and software-defined vehicles.

Global automotive microcontrollers market to reach $34.31B by 2035, driven by ADAS, electrification, and software-defined vehicles.

The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...

Market News
Bullish
3 hours ago
QuickLogic and PQSecure demo post-quantum cryptography on reprogrammable eFPGA for future-proof security.

QuickLogic and PQSecure demo post-quantum cryptography on reprogrammable eFPGA for future-proof security.

QuickLogic and PQSecure Technologies demonstrated that PQSecure's CRYSTAL-1000C post-quantum cryptographic IP can be efficiently implemented on QuickLogic's reprogrammable eFPGA fabric within SoCs. This allows field-upgradeable security without costl...

Market News
Bullish
4 hours ago
Relmada Therapeutics to report Q2 2026 financial results on August 6, 2026

Relmada Therapeutics to report Q2 2026 financial results on August 6, 2026

Relmada Therapeutics, a clinical-stage biotech company focused on oncology and CNS therapies, will announce its financial results for Q2 2026 on August 6, 2026. The company will host a conference call and webcast to discuss the results and recent bus...

Company Fundamentals
Neutral
4 hours ago
Gilat Satellite Networks to report Q2 2026 results on August 5 with CEO and CFO call.

Gilat Satellite Networks to report Q2 2026 results on August 5 with CEO and CFO call.

Gilat Satellite Networks Ltd., a global leader in satellite networking technology, will release its second quarter 2026 financial results on August 5, 2026. Following the release, CEO Adi Sfadia and CFO Gil Benyamini will hold a conference call and w...

Company Fundamentals
Neutral
4 hours ago
B&M's Q1 update splits analysts as Deutsche Bank upgrades but Panmure Liberum downgrades on growth doubts

B&M's Q1 update splits analysts as Deutsche Bank upgrades but Panmure Liberum downgrades on growth doubts

B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...

Analyst Insights
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App